Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 10/20 | 1.00 |
| ▸ | TDO2 | P48775 | 4/20 | 0.79 |
| ▸ | GSK3B | P49841 | 2/20 | 0.50 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25245762 | 0.99 | IDO1 (0.97) | IDO1TDO2GSK3BEGFRSRC | |
| SCHEMBL31265741 | 0.88 | IDO1 (1.00) | IDO1TDO2GSK3BEGFRSRC | |
| SCHEMBL5286855 | 0.88 | IDO1 (1.00) | IDO1TDO2GSK3BEGFRSRC | |
| SCHEMBL5528789 | 0.88 | IDO1 (1.00) | IDO1TDO2GSK3BEGFRSRC | |
| SCHEMBL1226606 | 0.88 | IDO1 (1.00) | IDO1TDO2GSK3BEGFRSRC | |
| SCHEMBL31550888 | 0.88 | IDO1 (1.00) | IDO1TDO2GSK3BEGFRSRC | |
| Hydrochloric Acid SCHEMBL9818269 | 0.87 | IDO1 (0.97) | IDO1TDO2GSK3BEGFRSRC | |
| SCHEMBL25762241 | 0.84 | IDO1 (0.72) | IDO1TDO2GSK3BEGFRSRC | |
| SCHEMBL6507505 | 0.83 | IDO1 (0.72) | IDO1TDO2GSK3BEGFRMAPT | |
| Hydrochloric Acid SCHEMBL25245765 | 0.81 | IDO1 (0.67) | IDO1TDO2GSK3BEGFRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023245162-A2 | COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION | TRAWSFYNYDD THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| CN-116685576-A | Cysteine protease inhibitors and methods of use thereof | 美商帕迪斯生物科学公司 | 2023-09-01 | — | — | CN | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2022-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | IDO1 1633/4885TDO2 2237/4885GSK3B 1161/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | IDO1 1859/4885TDO2 1845/4885GSK3B 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.